Adamis Pharmaceuticals (NASDAQ:ADMP) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Adamis Pharmaceuticals (NASDAQ:ADMP) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.06), Bloomberg Earnings reports. The firm had revenue of $5.90 million for the quarter, compared to analyst estimates of $6.55 million. Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%.

ADMP traded up $0.03 during trading on Wednesday, reaching $0.95. 11,845 shares of the company were exchanged, compared to its average volume of 709,349. The stock has a market cap of $62.05 million, a P/E ratio of -0.97 and a beta of 1.38. The firm has a 50 day moving average of $0.70 and a 200 day moving average of $1.16. The company has a current ratio of 1.04, a quick ratio of 0.79 and a debt-to-equity ratio of 0.05. Adamis Pharmaceuticals has a 52 week low of $0.48 and a 52 week high of $3.29.

Several equities research analysts recently issued reports on the company. B. Riley raised Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research report on Tuesday, July 23rd. Maxim Group set a $6.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 9th. ValuEngine raised Adamis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Zacks Investment Research raised Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $3.87.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

See Also: What are gap-down stocks?

Earnings History for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.